Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Incyte ( (INCY) ) has provided an announcement.
Incyte Corporation announced that board member Susanne Schaffert tendered her resignation from the company’s Board of Directors on March 26, 2026, with the departure to take effect on April 15, 2026. The company stated that Schaffert’s resignation, after serving on the board since 2022, was not due to any disagreement over operations, policies or practices, signaling a routine governance change rather than a shift in strategic direction.
The most recent analyst rating on (INCY) stock is a Buy with a $123.00 price target. To see the full list of analyst forecasts on Incyte stock, see the INCY Stock Forecast page.
Spark’s Take on INCY Stock
According to Spark, TipRanks’ AI Analyst, INCY is a Outperform.
The score is driven primarily by strong financial strength (low leverage) and the 2025 profitability/cash generation rebound, supported by positive 2026 guidance. The biggest offsets are weak current technical momentum and execution/regulatory risks highlighted by higher R&D needs and recent setbacks (Opsilora PN delay and the Zynyz CRL).
To see Spark’s full report on INCY stock, click here.
More about Incyte
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. The company primarily operates in specialty therapeutics, targeting serious unmet medical needs in oncology and other disease areas, and competes in the global market for novel targeted therapies and immunotherapies.
Average Trading Volume: 1,889,578
Technical Sentiment Signal: Buy
Current Market Cap: $17.97B
Find detailed analytics on INCY stock on TipRanks’ Stock Analysis page.